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Abstract
Background Nitric oxide and prostaglandin E2  (PGE2play
pivotal roles in both the pathogenesis of osteoarthritis and
catabolic processes in articular cartilage. These mediators are
influenced by both IL-1β and mechanical loading, and involve
alterations in the inducible nitric oxide synthase (iNOS) and
cyclo-oxygenase (COX)-2 enzymes. To identify the specific
interactions that are activated by both types of stimuli, we
examined the effects of dynamic compression on levels of
expression of iNOS and COX-2 and involvement of the p38
mitogen-activated protein kinase (MAPK) pathway.
Methods Chondrocyte/agarose constructs were cultured under
free-swelling conditions with or without IL-1β and/or SB203580
(inhibitor of p38 MAPK) for up to 48 hours. Using a fully
characterized bioreactor system, constructs were subjected to
dynamic compression for 6, 12 and 48 hours under similar
treatments. The activation or inhibition of p38 MAPK by IL-1β
and/or SB203580 was analyzed by western blotting. iNOS,
COX-2, aggrecan and collagen type II signals were assessed
utilizing real-time quantitative PCR coupled with molecular
beacons. Release of nitrite and PGE2 was quantified using
biochemical assays. Two-way analysis of variance and the post
hoc Bonferroni-corrected t-test were used to examine data.
Results IL-1β activated the phosphorylation of p38 MAPK and
this effect was abolished by SB203580. IL-1β induced a
transient increase in iNOS expression and stimulated the
production of nitrite release. Stimulation by either dynamic
compression or SB203580 in isolation reduced the IL-1β
induced iNOS expression and nitrite production. However, co-
stimulation with both dynamic compression and SB203580
inhibited the expression levels of iNOS and production of nitrite
induced by the cytokine. IL-1β induced a transient increase in
COX-2 expression and stimulated the cumulative production of
PGE2  release. These effects were inhibited by dynamic
compression or SB203580. Co-stimulation with both dynamic
compression and SB203580 restored cytokine-induced
inhibition of aggrecan expression. This is in contrast to collagen
type II, in which we observed no response with the cytokine and/
or SB203580.
Conclusion These data suggest that dynamic compression
directly influences the expression levels of iNOS and COX-2.
These molecules are current targets for pharmacological
intervention, raising the possibility for integrated
pharmacological and biophysical therapies for the treatment of
cartilage joint disorders.
Introduction
The mechanical environment is an important factor that main-
tains articular cartilage in a healthy state. Mechanical signals
generated under normal physiological loading conditions will
activate mechanotransduction pathways and drive biochemi-
cal events that regulate chondrocyte function and activity [1-
4]. It is well established that proinflammatory cytokines such
as IL-1β act as the key mediators of cartilage breakdown and
stimulate the release of nitric oxide (NO) and prostaglandin
(PG)E2, via induction of inducible isoforms of the nitric oxide
synthase (iNOS) and cyclo-oxygenase (COX)-2 enzymes [5-
9]. There is growing evidence that mechanical stimulation
inhibits the release of NO and PGE2 by articular chondrocytes
[10-18]. Thus, mechanical strain acts in an anti-inflammatory
COX = cyclo-oxygenase; Ct = cycle threshold; GAPDH = glyceraldehyde 3-phosphate dehydrogenase; IL = interleukin; iNOS = inducible isoforms 
of the nitric oxide synthase; JNK = c-Jun amino-terminal kinase; MAPK = mitogen-activated protein kinase; NF-κB = nuclear factor-κB; NO = nitric 
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manner that may influence the progression of osteoarthritis
(OA). However, the molecular mechanisms that underlie spe-
cific mechanotransduction pathways are complex and vary
depending on the type of mechanical stimuli and pathological
environment of the tissue.
The fundamental pathways that play a role in increasing the
release of NO and PGE2 by IL-1β involve activation of mem-
bers of the mitogen-activated protein kinase (MAPK) pathway,
namely extracellular signal-regulated kinase (ERK)-1/2, p38
and c-Jun amino-terminal kinase (JNK) families, and the tran-
scription factors activator protein-1 and nuclear factor-κB (NF-
κB) [19-27]. These studies demonstrated strong stimulation
of p38 MAPK by IL-1β and the subsequent induction of iNOS
and COX-2 expression in articular chondrocytes. Thus, the
potential of p38 MAPK as drug target in cartilage disease has
led to the development of several inhibitors by pharmaceutical
companies. However, no study has examined the involvement
of the p38 MAPK pathway in response to both IL-1β and
mechanical loading.
Mechanical stimulation in the form of static or intermittent com-
pression of varying loading modalities, including shear stress
or tension, may influence the signal transduction pathways
activated by IL-1β [28-37]. For instance, loading studies that
apply physiological levels of compression to chondrocytes
have demonstrated a role for the integrins in mediating the
mechanotransduction process, including downregulation of
NO and PGE2 release, both in the presence and absence of
IL-1β, utilizing iNOS and COX-2 specific inhibitors [16-
18,38,39]. The nature of the mechanical loading regimen and
model system will therefore determine whether mechanical
signals will prevent or induce these inflammatory mediators.
Accordingly, the present study examines the interplay
between mechano-sensitive and cytokine-sensitive pathways,
and determines the effects of IL-1β and dynamic compression
on the expression levels of iNOS and COX-2 and involvement
of the p38 MAPK pathway.
Materials and methods
Isolation of chondrocytes and culture in agarose 
constructs
This study involves bovine cells procured from a local abbatoir
with authorization from the relevant meat inspectors (Dawn
Cardington, Bedfordshire, UK). It does not involve humans,
human tissue, or experimentation on animals. Full-depth slices
of articular cartilage were dissected from the proximal surface
of the metacarpalphalangeal joints of 18-month-old cattle
[40,41] and diced. The tissue was then incubated on rollers
for 1 hour at 37°C in Dulbecco's modified Eagle's medium
(DMEM) supplemented with 20% (vol/vol) foetal calf serum
plus 2 μmol/l l-glutamine, 5 μg/ml penicillin, 5 μg/ml strepto-
mycin, 20 mmol/l Hepes buffer and 0.85 μmol/l l-ascorbic
acid, plus 700 units/ml pronase. It was subsequently incu-
bated for a further 16 hours at 37°C in medium supplemented
with 100 units/ml collagenase type XI (All Sigma Chemical
Co., Poole, UK). The chondrocyte suspension was washed
and cell viability assessed using trypan blue. Chondrocytes
were finally re-suspended in media at a cell concentration of 8
× 106 cells/ml. The cell suspension was added to an equal vol-
ume of molten 6% (weight/vol) agarose type VII (Sigma-
Aldrich, Poole, UK) in Earle's Balanced Salt Solution (Sigma
Chemical Co., Poole, UK) to yield a final cell concentration of
4 × 106 cells/ml in 3% (weight/vol) agarose. The cell/agarose
suspension was transferred into a sterile stainless steel mould,
containing holes 5 mm in diameter and 5 mm in height and
allowed to gel at 4°C for 20 minutes to yield cylindrical con-
structs. Chondrocyte/agarose constructs were equilibrated in
culture in 1 ml DMEM plus 1 × ITS liquid media supplement
(Sigma-Aldrich) at 37°C in 5% carbon dioxide for 24 hours.
Temporal effects of IL-1β under free-swelling conditions
Constructs were cultured in 1 ml DMEM + 1 × ITS supple-
mented with 0 or 10 ng/ml IL-1β (Peprotech EC Ltd, London,
UK) and/or 10 μmol/l SB203580 (4-[4-fluorophenyl]-2-[4-
methylsulfinylphenyl]-5-[4-pyridyl]1H-imidazole; a selective
inhibitor of p38 MAPK) [24,42] under free-swelling conditions
for 0, 0.75, 1.5, 3, 6, 12, 24, or 48 hours (Merck Chemicals,
Nottingham, UK). At the specified time points, representative
constructs were snap frozen in liquid nitrogen and stored at -
80°C before extraction of mRNA. The corresponding media
were stored at -20°C before biochemical analysis.
Application of dynamic compression
A fully characterised bioreactor system (Zwick Testing
Machines Ltd, Leominster, UK) was used to apply physiologi-
cal levels of dynamic compressive strain to chondrocyte/agar-
ose constructs, as detailed previously [38-41]. Equilibrated
constructs were transferred into individual wells of a 24-well
culture plate (Costar, High Wycombe, UK) and mounted
within the bioreactor apparatus. One millilitre of DMEM plus 1
× ITS was introduced into each well. The media were supple-
mented with 0 or 10 ng/ml IL-1β and/or 10 μmol/l SB203580.
Control constructs were unstrained but were maintained
within the bioreactor system. Strained constructs were sub-
jected to a dynamic compressive strain ranging from 0% to
15% in a sinusoidal waveform at a frequency of 1 Hz, as pre-
viously described [38-41]. The constructs were cultured at
37°C/5% carbon dioxide for 6, 12, or 48 hours. At the end of
each experiment, the constructs were snap frozen in liquid
nitrogen and stored at -80°C before extraction of mRNA. The
corresponding media were stored at -20°C before biochemi-
cal analysis.
Protein extraction and analysis by Western blotting
Following IL-1β stimulation, chondrocyte/agarose constructs
(n = 3) were washed with ice-cold phosphate-buffered saline
containing 100 μmol/l Na3VO4 and pulverized in ice-cold lysis
buffer containing 1% Igepal, 1 mmol/l Na3VO4 (both from
Sigma Aldrich) and protease inhibitor cocktail (RocheAvailable online http://arthritis-research.com/content/10/2/R35
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Diagostics, Lewes, UK). The cell/agarose lysis solution was
left on ice for 30 minutes and centrifuged at 13,000 rpm for
15 minutes. Supernatants were collected and protein concen-
tration was determined by Folin-Lowry method on the
Dynatech MR5000 microplate reader (Dynatech, Alexandria,
VA, USA). Equal amounts of protein (400 μg) were separated
by 12% SDS-PAGE and transferred to polyvinylidene fluoride
membranes (Millipore Immobilon-P; Sigma Aldrich). Mem-
branes were blocked in buffer containing 1 × Tris-buffered
saline (TBS) plus 0.1% Tween-20, and 1% nonfat milk for 2
hours at room temperature, and then washed five times with
TBS plus 0.1% Tween-20.
Membranes were incubated with a polyclonal rabbit antibody
for phospho-p38 MAPK (Thr180/Tyr182) at a dilution of
1:1,000 (New England Biolabs Ltd, Hitchin, UK). After wash-
ing extensively with TBS plus 0.1% Tween-20, membranes
were incubated with horseradish peroxidase-linked secondary
antibody for 1 hour and the binding was detected using
Enhanced Chemiluminescence Plus Western blotting detec-
tion system, in accordance with the manufacturer's instruc-
tions (Amersham, Buckinghampshire, UK). Membranes were
stripped with a solution containing 62.5 mmol/l Tris (pH 6.8),
2% SDS and 100 mmol/l β-mercaptoethanol for 30 minutes at
50°C, and then reprobed using a phosphorylation state-inde-
pendent antibody for p38 MAPK and α-tubulin, which served
as an internal control (Cell Signalling).
RNA extraction, cDNA synthesis and real-time PCR
Total RNA was isolated from individual constructs using pro-
tocols described in the QIAquick® Spin gel extraction and
Rneasy®  kits (Qiagen, West Sussex, UK), as previously
described [43]. Following the manufacturer's instructions,
Ambion's DNA-free DNase treatment and removal reagents
were used to eliminate any contaminating DNA from the RNA
sample (Ambion Applied Biosystems, Warrington, UK). RNA
was quantified using the Nanodrop ND-1000 spectrophotom-
eter (LabTech, East Sussex, UK) and stored in 40 μl RNase-
free water at -80°C until reverse transcription could be per-
formed using manufacturer's protocols from the Stratascript™
First-Strand cDNA synthesis kit (Stratagene, Amsterdam, The
Netherlands). Briefly, 200 ng of total RNA was reverse tran-
scribed in a 20 μl reaction volume using the manufacturer-sup-
plied oligo(dT) primers. Minus reverse transcriptase (NoRT)
control reactions were prepared for each sample by omitting
the Stratascript™ reverse transcriptase.
Real-time quantitative PCR assays coupled with molecular
beacons were performed in 25 μl reaction mixtures containing
1 μl cDNA, 12.5 μl Brilliant® QRT-PCR Master Mix, primer
pairs and probes listed in Table 1, and nuclease free PCR
grade water to 25 μl. Each sample was run in duplicate using
the 96-well thermal system of the MX3000P QPCR instru-
ment (Stratagene). Thermocycling conditions comprised an
initial polymerase activation step at 95°C for 10 minutes, fol-
lowed by 35 cycles at 95°C for 30 seconds, at 55°C for 1
minute and at 72°C for 1 minute. In order to screen for contam-
ination of reagents or false amplification, PCR controls were
prepared for each sample by preparing identical reaction mix-
tures except for the addition of the no template control (NTC).
NoRT (minus reverse transcriptase) controls were additionally
included in each PCR assay.
Molecular beacon design and characterization for real-
time PCR
Molecular beacons were introduced for real-time detection of
PCR products and were synthesized from oligonucleotides
(Sigma Genosys Limited, Cambridge, UK) using the Beacon
Designer software (Premier Biosoft International, California,
USA). Probes have a hairpin structure and contain fluorescein
(FAM) or 6-carboxyhexafluorescein (HEX) as the 5'-reporter
dye and 4-(4'-dimethylaminophenylazo)benzoic acid as the 3'-
quencher (Table 1). Sequences were designed to avoid
regions of cross homology and analyzed using the Basic Local
Alignment Search Tool to verify specificity. Additionally, tem-
plates were folded and secondary structures avoided using
MFold programme and beacon hairpin melting temperatures
were calculated using the Zucker software. Primer accession
numbers (EMBL [European Molecular Biology Laboratory];
Table 1) were obtained from previously published studies uti-
lizing bovine chondrocytes [44-46]. Primers used in PCR
experiments with molecular beacons produced amplicons,
which were between 70 and 82 base pairs (Table 1).
PCR efficiencies for optimal primer pair and probe concentra-
tions were derived from standard curves (n = 3) by preparing
a 10-fold serial dilution of cDNA from a sample that repre-
sented the untreated control at time zero conditions. The real-
time PCR efficiencies (E) of amplification for each target was
defined according to the following relationship: E = 10(-1/slope).
The R2 value of the standard curve exceeded 0.9998 and
revealed efficiency values presented in table 1.
Data normalization and statistical analyses
Fluorescence data was collected during the annealing stage
of amplification and data was analyzed using the MxPro™
QPCR software (version 3.0; Stratagene). Baselines and
thresholds were automatically set by the software and used
after manual inspection. The cycle threshold (Ct) value for
each duplicate reaction was expressed as the mean value and
the results were exported as tab-delimited text files into Micro-
soft Excel for further analysis. The data obtained by PCR assay
for glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
was validated as a reference gene by displaying the Ct values
as box and whisker plots, and the distribution examined under
free swelling and mechanical loading conditions (data not
shown). The Ct values for GAPDH remained stable with no
changes detected under all culture conditions, suggesting its
suitability as a reference gene.Arthritis Research & Therapy    Vol 10 No 2    Chowdhury et al.
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Relative quantification of iNOS, COX-2, aggrecan and colla-
gen type II signals was accomplished by normalizing each tar-
get gene to GAPDH and to the calibrator sample by a
comparative Ct approach [47,48]. For the free-swelling exper-
iments, the difference in cycle threshold (ΔCt) for the target
was calculated by subtracting the mean Ct value for the time
zero control (calibrator) from the Ct value of the target sample.
For the mechanical loading studies, ΔCt was calculated by
subtracting the mean Ct value for the unstrained, no treatment
control (calibrator) from the target sample. The ΔCt of the tar-
get was then normalized to the ΔCt of the reference gene,
namely GAPDH. Thus, for each sample, the ratio of the relative
expression level of target ΔCt and reference ΔCt was calcu-
lated, as shown in the following equation.
E represents the efficiencies obtained for the target and refer-
ence gene. ΔCttarget represents the difference in Ct values for
the mean calibrator or sample for the target gene. ΔCtRefer-
encerepresents the difference in Ct values for the mean calibra-
tor or sample for the reference gene GAPDH. Ratios were
expressed on a logarithmic scale (arbitrary units).
Nitrite and prostaglandin E2 analysis
Quantification of nitrite and PGE2 release were previously
described in detail [16-18,38]. Absolute concentrations of
nitrite (μmol/l), a stable end-product of NO, were determined
in the media using a spectrophotometric method based on the
Griess reaction. PGE2 production was measured in the culture
media using an enzyme immunoassay kit (Amersham Bio-
sciences, Buckinghamshire, UK).
Statistical analysis
For the time course studies under free-swelling conditions,
data represent the mean and standard error of the mean val-
ues of six replicates from three separate experiments. Two-
way analysis of variance and the post hoc Bonferroni-cor-
rected t-test was used to examine data for constructs cultured
in the presence or absence of IL-1β and/or SB203580. For
the mechanical loading experiments, data represent the mean
and standard error of the mean values of replicates indicated
in the individual figure legend. Statistical analysis was per-
formed by a two-way analysis of variance and the post hoc
Bonferroni-corrected t-tests to compare differences between
unstrained and strained constructs cultured under the differ-
ent treatment conditions. Data were also examined between
unstrained constructs cultured in the absence and presence
of the cytokine and/or inhibitor. In all cases, a level of 5% was
considered statistically significant (P < 0.05).
Results
IL-1β activates the phosphorylation of p38 MAPK
We examined the ability of IL-1β to activate the p38 pathway
by Western blot analysis using antibodies directed against the
Thr180/Tyr182 phosphorylated p38 (Figure 1). The activation
of p38 MAPK was detected 20 minutes after the addition of
IL-1β and declined thereafter, when compared with time zero.
Co-stimulation with IL-1β and the p38 MAPK inhibitor (10
μmol/l SB203580) abolished the activation of p38 at 20 min-
utes in chondrocyte/agarose constructs (Figure 1b).
Table 1
Description of the Beacon designer sequences used to quantify gene expression and real-time reaction efficiencies of PCR assays
Gene Accession 
number
Sequences Product size 
(base pairs)
Efficiency
iNOS U14640 Probe: 5'-FAM-CGCGATCCCTGCTTGGTGGCGAAGATGAGCGATCGCG-DABCYL-
3' Forward: 5'-GTAACAAAGGAGATAGAAACAACAGG-3' Reverse: 5'-
CAGCTCCGGGCGTCAAAG-3'
81 1.98 ± 0.06
COX-2 AF031698 Probe: 5'-FAM-CGCGATCGTCAGAAATTCGGGTGTGGTACAGTTGATCGCG-
DABCYL-3' Forward: 5'-CGAGGTGTATGTATGAGTGTAGG-3' Reverse: 5'-
GTTGGGAGTGGGTTTCAGG-3'
82 1.99 ± 0.03
Aggrecan U76615 Probe: 5'-FAM-CGCGATCCACTCAGCGAGTTGTCAGGTTCTGAGATCGCG-
DABCYL-3' Forward: 5'-TGGTGTTTGTGACTCTGAGG-3' Reverse: 5'-
GATGAAGTAGCAGGGGATGG-3'
79 1.97 ± 0.05
Collagen 
type II
X02420 Probe: 5'-FAM-CGCGATGCGTCAGGTCAGGTCAGCCATATCGCG-DABCYL-3' 
Forward: 5'-AAACCCGAACCCAGAACC-3' Reverse: 5'-
AAGTCCGAACTGTGAGAGG-3'
70 2.00 ± 0.05
GAPDH U85042 Probe: 5'-HEX-CGCGATCCACCATCTTCCAGGAGCGAGATCCGATCGCG-
DABCYL-3' Forward: 5'-TTCAACGGCACAGTCAAGG-3' Reverse: 5'-
TTCAACGGCACAGTCAAGG-3'
75 2.03 ± 0.01
The Beacon Designer software was used to design forward and reverse primer and probe sequences for molecular beacon applications and were 
synthesized by Sigma Genosys Ltd, Cambridge, UK. Secondary structures were avoided using the Mfold programme and sequences were 
analyzed using Basic Local Alignment Search Tool to verify specificity. Probes contain fluorescein (FAM) or 6-carboxyhexafluorescein (HEX) as a 
5'-reporter dye and 4-(4'-dimethylaminophenylazo)benzoic acid (DABCYL) as 3'-quencher. Note that the arm sequences are underlined. COX, 
cyclo-oxygenase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; iNOS, inducible nitric oxide synthase.
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IL-1β induced iNOS and COX-2 and inhibited aggrecan 
expression
Figure 2 illustrates the effects of IL-1β on the relative expres-
sion levels of iNOS, COX-2, aggrecan and collagen type II in
constructs cultured under free-swelling conditions in the pres-
ence and absence of the p38 MAPK inhibitor SB203580. In
the absence of the cytokine, the expression levels of iNOS and
COX-2 appeared to decrease over a period of 48 hours when
compared with time zero (Figure 2 panels a and b, respec-
tively). However, the level of downregulation was not statisti-
cally significant when compared with time zero. IL-1β induced
a transient increase in iNOS levels, with a peak in expression
levels at 6 hours (sevenfold increase; P < 0.001) and 12 hours
(fourfold increase; P < 0.05), which decreased thereafter (Fig-
ure 2a). At 6 hours, SB203580 partially reduced the IL-1β
induced expression of iNOS to approximately fourfold when
compared with constructs treated with IL-1β only (P < 0.01;
Figure 2a). The IL-1β induced iNOS expression was downreg-
ulated with the p38 MAPK inhibitor at 12 hours (P < 0.01; Fig-
ure 2a). The induction of COX-2 by IL-1β was detected at 3
hours (fourfold increase; P  < 0.05) and 6 hours (14-fold
increase; P < 0.001), with a peak in expression at 12 hours
(19-fold increase; P < 0.001) when compared with time zero
(Figure 2b). The presence of SB203580 inhibited the IL-1β
induced expression of COX-2 (P < 0.05 at 3 hours; P < 0.001
at 6 and 12 hours; Figure 2b).
In the absence of the cytokine, there was a downregulation of
aggrecan expression up to 6 hours of culture when compared
with time zero (Figure 2c). Aggrecan expression levels peaked
at 12 hours (threefold increase; P < 0.01; Figure 2c) when
compared with time zero and was not significantly detected at
any other time point. At 12 hours, aggrecan expression was
inhibited by the presence of the cytokine (P < 0.001) but was
not significantly influenced by the addition of SB203580 (Fig-
ure 2c). In contrast, the expression levels of collagen type II
appeared to be consistently downregulated in the presence or
absence of the cytokine or with the addition of the inhibitor
(Figure 2d). However, the level of inhibition under the various
treatment conditions did not differ significantly relative to that
at time zero.
IL-1β stimulates the production of nitrite and PGE2 
release
The cumulative production of nitrite and PGE2 release were
assessed as presented in Figure 3. In the absence of the
cytokine, the levels of nitrite and PGE2 release did not change
over the 48-hour culture period. IL-1β induced nitrite and
PGE2 release with significant differences measured at 24 and
48 hours (all P < 0.001; Figure 3 panels a and b, respectively).
SB203580 partially reduced the IL-1β induced nitrite release
at 24 hours (24 μmol/l decrease to 14 μmol/l) and at 48 hours
(46 μmol/l decrease to 29 μmol/l). SB203580 abolished the
IL-1β induced PGE2 release to basal levels (both P < 0.05;
Figure 3b).
Dynamic compression inhibited IL-1β induced iNOS and 
COX-2 expression, production of nitrite and PGE2 
release
The relative expression levels of iNOS expression in
unstrained constructs and constructs subjected to 15%
dynamic compressive strain for 6, 12 and 48 hours are pre-
sented in Figure 4. The temporal profile of iNOS expression in
response to IL-1β was similar to that in free-swelling culture,
with a peak in expression at 6 hours (P < 0.001; Figure 4a).
However, the magnitude of the peak expression induced by
the cytokine was markedly greater than under free-swelling
conditions, with approximately 145-fold increase in unstrained
constructs (Figure 4a) as compared with sevenfold increase in
free-swelling culture (Figure 4a). Stimulation by dynamic com-
pression or SB203580 in isolation significantly reduced the
IL-1β induced iNOS expression at both 6 and 12 hours (both
P  < 0.001; Figure 4a,b). However, co-stimulation with
dynamic compression and the inhibitor produced an effect
greater than each in isolation and resulted in iNOS expression
returning to basal values (Figure 4a,b,c). iNOS induction at 6
Figure 1
Activation of p38 MAPK by IL-1β Activation of p38 MAPK by IL-1β. p38 phosphorylation by IL-1β in 
chondrocyte/agarose constructs cultured under free-swelling condi-
tions (a) in the presence or absence of 10 ng/ml IL-1β for up to 45 min-
utes or (b) with IL-1β and 10 μmol/l SB203580 for 20 minutes. 
Phospho-p38 MAPK was analyzed for each test condition using a 
phosphorylation state specific anti-p38 (Thr180/Tyr182) antibody 
(upper panel), against total p38 MAPK (middle panel) and α-tubulin as 
a loading control (lower panel). All cell extracts were subjected to 
Western blot analysis. Each band corresponds to three constructs 
pooled from two separate experiments. MAPK, mitogen-activated pro-
tein kinase; UT, untreated.Arthritis Research & Therapy    Vol 10 No 2    Chowdhury et al.
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and 12 hours closely correlated with the production of nitrite,
which was maximal after 48 hours of incubation with the
cytokine (P  < 0.001; Figure 4d). The IL-1β induced nitrite
release was inhibited by dynamic compression in the absence
and presence of SB203580 (both P < 0.001; Figure 4d).
The temporal profile of COX-2 expression in unstrained and
strained constructs, cultured for 6, 12 and 48 hours, is shown
in Figure 5. The induction of COX-2 expression in response to
IL-1β was similar to that in free-swelling culture, with peak
expression at 12 hours (P < 0.001; Figure 5b). The relative
magnitudes of the peak expression at 12 hours with the
cytokine were 20-fold (Figure 2b) and 44-fold (Figure 5b) in
free-swelling and unstrained constructs, respectively. The
application of dynamic compression or presence of
SB203580 reduced the IL-1β induced COX-2 expression at
6 hours (P < 0.01; Figure 5a). Stimulation by dynamic com-
pression or SB203580 alone for 12 hours inhibited the
cytokine-induced induction of COX-2 (both P < 0.001; Figure
5b). Co-stimulation with both dynamic compression and
SB203580 had no further effect when compared with each in
isolation at 12 hours (Figure 5b), with values returning to basal
levels at 48 hours (Figure 5c). COX-2 expression correlated
with PGE2 production with levels unaltered in unstrained and
strained constructs cultured for 48 hours under no treatment
conditions (Figure 5d). Dynamic compression (P < 0.01) or
the presence of SB203580 (P < 0.001) alone abolished the
IL-1β induced PGE2 release (Figure 5d). However, co-stimula-
tion with both dynamic compression and SB203580 had no
further effect compared with each in isolation (Figure 5d).
Dynamic compression restored IL-1β induced inhibition 
of aggrecan expression
The expression levels for aggrecan and collagen type II in
unstrained constructs and constructs subjected to dynamic
compressive strain for 6, 12 and 48 hours are shown in Figure
Figure 2
IL-1β stimulates iNOS and COX-2 expression IL-1β stimulates iNOS and COX-2 expression. Temporal profile of IL-1β on (a) iNOS, (b) COX-2, (c) aggrecan and (d) collagen type II expression 
by chondrocyte/agarose constructs cultured under free-swelling conditions with 0 or 10 ng/ml IL-1β and/or 10 μmol/l SB203580. Bars represent 
the mean and standard error of the mean of six replicates from three separate experiments. The ratio of the relative expression level for the target 
gene was calibrated to the mean value at time = 0 and normalized to the reference gene GAPDH. Ratios were expressed on a logarithmic scale 
(arbitrary units). Two-way analysis of variance with post hoc Bonferroni-corrected t-tests was used to compare data under the different treatments: 
*P < 0.05, **P < 0.01 and ***P < 0.001 for comparisons between time zero with IL-1β; +P < 0.05, ++P < 0.01 and +++P < 0.001 for comparisons 
between untreated with IL-1β or IL-1β with IL-1β plus SB203580. COX, cyclo-oxygenase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; 
iNOS, inducible isoforms of the nitric oxide synthase.Available online http://arthritis-research.com/content/10/2/R35
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6. In the absence of the cytokine, dynamic compression
increased aggrecan expression to approximately threefold at
12 hours (P < 0.001; Figure 6a). IL-1β inhibited aggrecan
expression in unstrained constructs at 6, 12 and 48 hours (all
P < 0.05), and the levels were not influenced significantly by
dynamic compression. However, co-stimulation with dynamic
compression and SB203580 increased aggrecan expression
at 12 hours (P < 0.05; Figure 6a). By contrast, the expression
levels of collagen type II were not influenced by dynamic com-
pression at 6, 12, or 48 hours in the presence or absence of
the cytokine (Figure 6b). Moreover, the presence of the p38
MAPK inhibitor did not significantly influence collagen type II
expression in unstrained or strained constructs.
Discussion
IL-1β plays a pivotal role in both the pathogenesis of OA and
as a potent mediator of catabolic processes in articular
chondrocytes. The inflammatory process involves the exces-
sive production of NO, PGs, matrix metalloproteinases, aggre-
canases, and cytokines associated with the IL-1 and tumour
necrosis factor families [5-9]. The net result is a tissue milieu
with increased levels of inflammatory mediators that lead to
cellular stress, chondrocyte apoptosis and loss of matrix tissue
[5-9]. There is clinical evidence to support the beneficial
effects of controlled moderate exercise in relieving adults with
OA, in combination with chondroprotective agents [49,50].
However, the success of these treatments largely relies on the
validation of the drugs and their pathophysiological interac-
tions within the OA affected joint. Consequently, in vitro biore-
actor systems have been developed as model systems to
investigate the mechano-sensitive and cytokine-sensitive intra-
cellular pathways. More specifically, a number of studies have
shown that the application of controlled loading regimens at
physiological magnitude prevents the harmful effects of IL-1β
by blocking the release of NO, PGE2 and matrix metalloprotei-
nases, and restoring extracellular matrix production [10-
18,38,39,45,46]. Consequently, the tissue maintains a bal-
ance in matrix turnover and regulates cytokine-induced path-
ways during articular cartilage loading.
In the present study, we utilized real-time quantitative PCR
assays coupled with a novel fluorescent probe known as the
molecular beacon to detect the catabolic (iNOS and COX-2)
and anabolic (aggrecan and collagen type II) genes utilizing
the chondrocyte/agarose model in conjunction with a well
characterized bioreactor system [40,41]. The data provide
striking evidence that dynamic compression antagonizes the
IL-1β induced expression of iNOS and COX-2 levels and pro-
duction of NO and PGE2 release. Additionally, we provide evi-
dence to support restoration of aggrecan levels by both types
of stimuli. These data support our previous studies that show
that dynamic compression counteracts the IL-1β induced
production of NO and PGE2  release by full-depth
chondrocytes and superficial zone chondrocytes, and restores
cell proliferation and proteoglycan synthesis [16,17].
The free-swelling studies were undertaken to determine how
the cytokine influenced gene expression levels with time, in the
absence of the bioreactor system. IL-1β activated the phos-
phorylation of p38 MAPK and was inhibited by the p38 MAPK
inhibitor (Figure 1). The cytokine additionally induced a tran-
sient increase in the expression levels of both iNOS and COX-
2 (Figure 2). COX-2 expression appeared to be more sensitive
to the cytokine and to the presence of SB203580 (Figure 2b),
suggesting that COX-2 activation may occur independently of
NO and primarily involves a p38 MAPK dependent pathway.
We observed a similar effect with the release of NO (Figure
3a) and PGE2 production (Figure 3b) in response to IL-1β, in
which SB203580 had a more potent effect on PGE2 release
Figure 3
IL-1β stimulates the production of nitrite and PGE2 release IL-1β stimulates the production of nitrite and PGE2 release. Tempo-
ral profile of IL-1β on the production of (a) nitrite and (b) PGE2 release 
by chondrocyte/agarose constructs cultured under free-swelling condi-
tions with 0 or 10 ng/ml IL-1β and/or 10 μmol/l SB203580. Bars repre-
sent the mean and standard error of the mean of six replicates from 
three separate experiments. Two-way analysis of variance with post hoc 
Bonferroni-corrected t-tests was used to compare data under the dif-
ferent treatments: *P < 0.05 and ***P < 0.001 for comparisons 
between time zero with IL-1β; +P < 0.05, ++P < 0.01 and +++P < 0.001 
for comparisons between untreated with IL-1β or IL-1β with IL-1β plus 
SB203580. PG, prostaglandin.Arthritis Research & Therapy    Vol 10 No 2    Chowdhury et al.
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than on NO production. It could be argued that the p38 MAPK
inhibitor may have nonspecific effects. Previous studies have
shown inhibition of NO release by SB203580 at a concentra-
tion of 1 and 10 μmol/l in IL-1β treated chondrocytes [20-
22,24,51]. However, at concentrations at 10 μmol/l or greater,
SB203580 was demonstrated to inhibit JNK in chondrocyte
monolayers, suggesting less specificity at a higher dose [52].
Accordingly, iNOS induction and NO release may therefore
involve activation of multiple MAPK pathways, in particular
JNK. A number of previous studies have reported differential
mechanisms through which IL-1β upregulates iNOS and
COX-2 expression that involve activating transcription factor-
2, NF-κB, IL-6, cAMP responsive element binding protein-1, or
activator protein-2 transcription factors and activation of all
members of the MAPKs [20,23,53]. Nevertheless, NF-κB
appears to be the primary transcription factor that influences
iNOS expression and NO production, and has been shown to
strongly inhibit PGE2 synthesis in OA affected cartilage [52].
Our studies utilizing human chondrocyte/agarose constructs
cultured with selective inhibitors of iNOS (1400W) and COX-
2 (NS-398), also suggest that NO could have a negative
influence on PGE2 production [18]. However, whether NO
induces or suppresses PGE2 release in the presence of IL-1β
remains controversial [9,18,54].
In separate experiments, constructs were subjected to
dynamic compression or remained unstrained within a biore-
actor system. The present data shows that unstrained culture
within the bioreactor system induced a significant enhance-
ment in the levels of NO release in the presence and absence
of IL-1β (Figure 4d), when compared with free-swelling culture
conditions (Figure 2a), whereas PGE2 release (Figures 2b and
5d) was largely unaffected, a phenomenon that concurs with
our previous studies [16,17]. A similar effect was noted for
iNOS induction in response to IL-1β, with a sevenfold increase
in free-swelling conditions (Figure 2a), as compared with a
145-fold increase in unstrained constructs cultured within the
bioreactor without the application of dynamic compression
Figure 4
Dynamic compression inhibits IL-1β induced iNOS expression and production of nitrite release Dynamic compression inhibits IL-1β induced iNOS expression and production of nitrite release. Effects of 15% dynamic compressive strain 
on (a,b,c) iNOS expression and (d) nitrite production in unstrained and strained constructs cultured under no treatment conditions or with 10 ng/ml 
IL-1β and/or 10 μmol/l SB203580 for 6, 12 and 48 hours. The ratio of the relative expression level of iNOS was calibrated to the mean value for the 
unstrained (untreated) control and normalized to GAPDH. Ratios were expressed on a logarithmic scale (arbitrary units). Bars represent the mean 
and standard error of the mean of 16 to 18 replicates from four separate experiments. Two-way analysis of variance with post hoc Bonferroni-cor-
rected t-tests was used to compare data: **P < 0.01 and ***P < 0.001. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; iNOS, inducible iso-
forms of the nitric oxide synthase.Available online http://arthritis-research.com/content/10/2/R35
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(Figure 4a). In accordance with the PGE2 release data, the fold
increase in expression of COX-2 was broadly similar under
both culture conditions (Figures 2b and 5). There are marked
differences in the diffusional constraints in unstrained con-
structs in the bioreactor, involving contact of the upper surface
with a fluid impermeable loading pin. Accordingly, the mass
transport of oxygen into the construct may be impaired, lead-
ing to increased hypoxia in the bioreactor system, compared
with constructs cultured under free-swelling conditions. A
number of recent studies support the hypothesis that oxygen
tension can influence the production of inflammatory media-
tors in cartilage. For example, hypoxia dramatically increased
iNOS expression and NO production by bovine chondrocytes
in response to IL-1β, whereas COX-2 expression was not
strongly influenced by oxygen tension [44,55,56].
Co-stimulation with dynamic compression and inhibitor for 6
hours completely abolished iNOS induction in response to IL-
1β (Figure 4a). Interestingly, neither dynamic compression or
the inhibitor alone were able to abolish the IL-1β induced
iNOS expression. The effect was more striking for COX-2 with
levels returning to basal values after application of dynamic
compression or the p38 MAPK inhibitor alone for 12 hours
(Figure 5b). The data suggest interactions between mechano-
sensitive and p38 MAPK dependent pathways in mediating
the inhibitory effect of dynamic compression on iNOS and
COX-2 expression. The importance of these findings is sup-
ported by recent studies utilizing monolayer chondrocytes,
which showed sustained levels of iNOS and COX-2
expression in response to IL-1β for up to 24 hours, with a dra-
matic reduction by cyclic tensile strain for 8 hours over a 24-
hour loading regimen [15]. Additionally, the mechanism was
shown to involve NF-κB activation, which could act down-
stream of p38 MAPK [13]. Nonetheless, static or intermittent
compression of different magnitudes applied to cartilage
explants increased NO and PGE2 production [28,29]. These
Figure 5
Dynamic compression inhibits IL-1β induced COX-2 expression and production of PGE2 release Dynamic compression inhibits IL-1β induced COX-2 expression and production of PGE2 release. Effects of 15% dynamic compressive strain 
on (a,b,c) COX-2 expression and (d) PGE2 production in unstrained and strained constructs cultured under no treatment conditions or with 10 ng/
ml IL-1β and/or 10 μmol/l SB203580 for 6, 12 and 48 hours. The ratio of the relative expression level of COX-2 was calibrated to the mean value for 
the unstrained (untreated) control and normalized to GAPDH. Ratios were expressed on a logarithmic scale. Bars represent the mean and standard 
error of the mean of 16 to 18 replicates from four separate experiments. Two-way analysis of variance with post hoc Bonferroni-corrected t-tests was 
used to compare data: **P < 0.01 and ***P < 0.001. COX, cyclo-oxygenase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; PG, 
prostaglandin.Arthritis Research & Therapy    Vol 10 No 2    Chowdhury et al.
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differences may potentially be attributed to both the nature of
the mechanical stimulus and the level of oxygen tension, as
indicated in recent studies [56-58].
We initially examined the involvement of the p38 MAPK
because this kinase was influenced by either IL-1β or mechan-
ical loading [24,52]. We demonstrated activation of the p38
MAPK following 20 minutes of stimulation with the cytokine
(Figure 1). However, a major limitation of the bioreactor system
is the time taken to retrieve constructs at the end of an exper-
iment (up to 10 minutes). This causes difficulties associated
with analyzing transient phosphorylation events, because alter-
ations in activation state may occur after the end of the
mechanical loading regimen. Accordingly, the time courses of
phosphorylation events in response to both IL-1β and dynamic
compression are not presented here, but work is actively
ongoing. In addition, we feel that the regulation of the IL-1β
pathways may be through many factors, and dynamic
Figure 6
IL-1β and dynamic compression influences aggrecan expression but not collagen type II IL-1β and dynamic compression influences aggrecan expression but not collagen type II. Effects of 15% dynamic compressive strain on (a) 
aggrecan and (b) collagen type II expression in unstrained (-) and strained (+) constructs cultured under no treatment conditions or with 10 ng/ml IL-
1β and/or 10 μmol/l SB203580 for 6, 12 and 48 hours. The ratio of the relative expression levels of the target gene was calibrated to the mean 
value for the unstrained (untreated) control and normalized to GAPDH. Ratios were expressed on a logarithmic scale (arbitrary units). Bars represent 
the mean and standard error of the mean of 10 replicates from three separate experiments. Two-way analysis of variance with post hoc Bonferroni-
corrected t-tests was used to compare data: *P < 0.05 and ***P < 0.001 between unstrained and strained values; and +P < 0.05 between 
untreated and IL-1β in unstrained constructs.Available online http://arthritis-research.com/content/10/2/R35
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compression may actually target a global mechanism involving
JNK or NF-κB, as indicated in previous studies [13,51,52].
In addition to the regulation of iNOS and COX-2 by dynamic
compression, co-stimulation with the inhibitor was important in
restoring the cytokine-induced inhibition of aggrecan expres-
sion. This is in contrast to collagen type II, in which no
response to IL-1β or dynamic compression was observed. It is
highly likely that matrix gene expression is controlled by tran-
sient factors, and could involve rapid activation of multiple tran-
scription factors that are influenced by a combination of
mechanical loading and IL-1β [19,22,31,32]. Consequently,
the multiple events activated in a time-dependent manner will
influence the rate of expression and assembly of the extracel-
lular matrix molecules, causing flare-ups in gene expression
levels. This phenomenon may start as early as 1 hour after
mechanical stimulation, as reported with aggrecan and colla-
gen type II expression [37,59].
Overall, these observations indicate a hypothetical mechanism
for the activation of iNOS by IL-1β that are, respectively,
dependent on p38 MAPK signalling and could involve activa-
tion of other MAPKs. In free-swelling conditions the p38 inde-
pendent pathway is predominantly activated, as indicated by
the partial effect of the p38 inhibitor on iNOS expression at
later time points. However, at early time points the p38 inhibi-
tor blocked activation of the p38 MAPK. Incorporation of the
construct into the bioreactor system, with its inherent
diffusional constraints, dramatically enhances iNOS induction,
potentially via preferential activation of the p38 MAPK depend-
ent pathway and possibly through a hypoxia-driven mecha-
nism. Accordingly, the inhibitor has a greater effect on iNOS
expression under these conditions. Dynamic compression
substantially reduces iNOS expression and co-stimulation
with both dynamic compression and the p38 MAPK inhibitor
abolished iNOS expression when compared with each in iso-
lation, suggesting that dynamic compression targets the p38
MAPK dependent pathway. By contrast, COX-2 activation by
IL-1β appears to be primarily mediated by a p38 MAPK
dependent pathway that is largely unaffected by transfer to the
bioreactor system but is highly susceptible to the p38 MAPK
inhibitor or dynamic compression. In addition to the regulation
of iNOS and COX-2 expression by dynamic compression, co-
stimulation with the inhibitor was important in restoring the
cytokine-induced inhibition of aggrecan expression. This is in
contrast to collagen type II, in which we observed no
response. It is probable that matrix gene expression is control-
led by transient factors and could involve rapid activation of
multiple MAPKs and transcription factors. Ultimately, elucida-
tion of the intracellular pathways will enable the identification
of appropriate pharmacological agents and provide a clinical
rationale for promoting the benefits of controlled physical
activity to manage and treat OA.
Conclusion
It is important to define the mechanistic pathways induced by
physiologically relevant mechanical signals in the presence of
proinflammatory mediators, because this information will pro-
vide key parameters for the safe application of pharmacologi-
cal therapies, in conjunction with biophysical treatments for
OA.
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